Evidence map›Paper›PMID 32452831›Full record

ArticleAging2020

Pyrrolo [3,4-

Danping Wang, Zhi Nie, Xiaoyan Jiang, Jinxiang Ye, Zhimin Wei, Dating Cheng, Chenyang Wang, Yingying Wu, Rong Liu, Haijun Chen and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Aging, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Danping WangDepartment of Pathology, First Affiliated Hospital of Kunming Medical University, Kunming 650032, Yunnan, China.
Zhi NieDepartment of Neurology, First Affiliated Hospital of Kunming Medical University, Kunming 650032, Yunnan,, China.
Xiaoyan JiangMedical Faculty of Kunming University of Science and Technology, Kunming 650500, China.
Jinxiang YeCollege of Chemistry, Fuzhou University, Fuzhou 350116, Fujian, China.
Zhimin WeiDepartment of Pathology, The Affiliated Hospital of Qingdao University, Qingdao 266071, China.
Dating ChengDepartment of Pathology, First Affiliated Hospital of Kunming Medical University, Kunming 650032, Yunnan, China.
Chenyang WangDepartment of Pathology, First Affiliated Hospital of Kunming Medical University, Kunming 650032, Yunnan, China.
Yingying WuDepartment of Pathology, First Affiliated Hospital of Kunming Medical University, Kunming 650032, Yunnan, China.
Rong LiuKey Laboratory of Animal Models and Human Disease Mechanisms of the Chinese Academy of Sciences and Yunnan Province, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming 650223, China.
Haijun ChenCollege of Chemistry, Fuzhou University, Fuzhou 350116, Fujian, China.
Ceshi ChenKey Laboratory of Animal Models and Human Disease Mechanisms of the Chinese Academy of Sciences and Yunnan Province, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming 650223, China.
Chunyan WangDepartment of Pathology, First Affiliated Hospital of Kunming Medical University, Kunming 650032, Yunnan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Triple-negative breast cancer (TNBC) has a poorer prognosis than other subtypes of breast cancer; however, it lacks effective targeted therapies clinically. In this study, we found FZU-0038-056, a novel compound derived from last-stage functionalization of tetrahydro-β-carboline scaffold, showed the most potent anti-cancer activity against TNBC cells among the 42 synthesized derivatives. We found FZU-0038-056 significantly induces apoptosis in HCC1806 and HCC1937 TNBC cells. FZU-0038-056 reduces the expression levels of several anti-apoptosis proteins, including Bcl-2, Mcl-1 and XIAP. Furthermore, we found FZU-0038-056 induces apoptosis partially through inhibiting the expression of Bcl-2. Finally, we found FZU-0038-056 significantly suppresses HCC1806 xenograft tumor growth in nude mice without affecting their body weight. Therefore, FZU-0038-056 has the potential to be a new anticancer agent for treating human TNBC.

Indexed as

AminesAnimalsAntineoplastic AgentsApoptosisApoptosis Regulatory ProteinsCarbolinesCell Line, TumorFemaleHeterocyclic CompoundsHumansMiceMice, NudeMyeloid Cell Leukemia Sequence 1 ProteinProto-Oncogene Proteins c-bcl-2PyrrolesQuinolinesAminesAntineoplastic AgentsApoptosis Regulatory ProteinsCarbolinesHeterocyclic CompoundsMyeloid Cell Leukemia Sequence 1 ProteinProto-Oncogene Proteins c-bcl-2PyrrolesQuinolinestryptolineX-Linked Inhibitor of Apoptosis ProteinapoptosisBcl-2tetrahydro-β-carboline derivativestriple-negative breast cancer

Identifiers

PMID32452831
PMCPMC7288966

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.